Earnings Feed
Start Free
ADMA BIOLOGICS, INC.·4

Feb 11, 9:00 PM ET

ELMS STEVE 4

4 · ADMA BIOLOGICS, INC. · Filed Feb 11, 2026

Research Summary

AI-generated summary of this filing

Updated

ADMA Director Steve Elms Receives RSU Awards

What Happened

  • Steve Elms, a director of ADMA Biologics (ADMA), was reported to have received two award-type acquisitions on Feb 9, 2026: 10,690 restricted stock units (RSUs) and 17,730 derivative shares. Both awards were reported at $0 per share (typical for RSU grants).
  • The 10,690 RSUs will vest in two equal installments on the six- and 12‑month anniversaries of the grant, becoming fully vested on the one‑year anniversary, subject to Mr. Elms’s continued service. The 17,730 are reported as derivative securities; a footnote indicates these relate to shares owned by a fund (see Key Details).

Key Details

  • Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (appears timely).
  • Reported prices/values: $0.00 per share for both reported acquisitions (typical for equity awards).
  • Shares owned after transaction (per filing footnote): effectively 98,020 securities counted for Mr. Elms (includes 10,690 RSUs granted Feb 9, 2026; 5,445 RSUs vesting Feb 19, 2026 from a prior grant; and 81,885 common shares owned).
  • Footnotes of note:
    • F1: 10,690 RSUs vest in two equal installments at 6 and 12 months (subject to continued service).
    • F2: Breaks down the post-transaction beneficial count (10,690 RSUs from Feb 9, 2026; 5,445 RSUs from Feb 19, 2025; 81,885 owned shares).
    • F3: The 17,730 derivative shares are owned of record by Aisling Capital II LP; Mr. Elms is Aisling’s Board designee and may be deemed to have beneficial ownership but disclaims beneficial ownership except to the extent of any pecuniary interest.
    • F4: Related options (where applicable) vest in 12 equal monthly installments.
  • Filing timeliness: Filed Feb 11 for a Feb 9 transaction (within the normal 2-business-day reporting window).

Context

  • This was an award/grant (not a market purchase or sale), which is common for director compensation and does not itself signal a buying or selling decision by the insider.
  • The 10,690 RSUs are time‑vesting and will convert to shares only if Mr. Elms remains in service through the vesting dates. The 17,730 derivative position is connected to a fund (Aisling) for which Mr. Elms is a designee; he disclaims direct beneficial ownership beyond any pecuniary interest.

Insider Transaction Report

Form 4
Period: 2026-02-09
ADMA BIOLOGICS, INC.ADMA
ELMS STEVE
Director
Transactions
  • Award

    Common Stock

    [F1][F2]
    2026-02-09+10,690→ 98,020 total
  • Award

    Stock Option (Right to Buy)

    [F4]
    2026-02-09+17,730→ 17,730 total
    Exercise: $16.37Exp: 2036-02-09→ Common Stock (17,730 underlying)
Holdings

  • Common Stock

    [F3]
    (indirect: See footnote)
    2,031,730
Footnotes (4)
  • [F1]These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
  • [F2]Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 81,885 shares of common stock owned by the Reporting Person.
  • [F3]These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Issuer and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.
  • [F4]These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
Signature
/s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact|2026-02-11

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4